HPLC Method Validation in Pharmaceutical Analysis
ICH-aligned validation parameters for assay and impurity methods in QC laboratories.
By Sarah Chen, MSc5 min read
Reviewed by Dr. Khalid Mehmood, MD ·
High-performance liquid chromatography (HPLC) remains the workhorse of pharmaceutical quality control. A method that “works on the bench” is not enough for release testing: regulators expect documented evidence that the procedure is suitable for its intended use. Validation, aligned with ICH Q2, turns a laboratory method into a defensible specification tool.
Intended use drives the protocol
Before collecting a single chromatogram, define what the method must decide. An assay of a finished tablet has different risk than a related-substance method for a potent impurity, or a dissolution-sample assay with a short run time. Write the intended use in one sentence, then map each ICH parameter to a pass/fail criterion that matches that sentence. Specificity for an impurity method is not the same as specificity for a content assay.
Typical protocol elements include system suitability limits, sample preparation robustness, and the concentration range that covers both specification and expected process variation. Include a placebo or matrix blank when excipients, dissolution media, or extractables could interfere.
Core ICH Q2 parameters
- Specificity: Resolve the analyte from known impurities, degradation products, and placebo peaks. Forced-degradation samples (acid, base, oxidant, heat, light) show whether the method is stability-indicating.
- Linearity and range: Cover at least 80–120% of the assay label claim, or from the reporting threshold to 120% of the impurity limit. Report slope, intercept, residual plots, and correlation — not only r².
- Accuracy: Spike placebo or drug product at three levels; recoveries should sit within a pre-set window (commonly 98–102% for assay, wider for trace impurities).
- Precision: Repeatability (same day, same analyst) and intermediate precision (different days, columns, or analysts) quantify random error. Report %RSD against a justified limit.
- Detection and quantitation limits: For impurities, establish LOD/LOQ from signal-to-noise or from the calibration residual, then confirm with independently prepared solutions.
- Robustness: Deliberately vary pH, organic ratio, flow, column temperature, and wavelength by small increments. Record which changes move retention or resolution outside system suitability.
System suitability is ongoing validation
Validation is a snapshot. Every sequence still needs system suitability: tailing, theoretical plates, resolution between critical pairs, and injection precision. If suitability fails, do not “average it out” — stop, diagnose (column, mobile phase, injector), and only then inject samples. Keep a change-control record when a column lot, detector lamp, or software version changes; a brief bridging check is cheaper than a failed inspection.
Document calculations, chromatograms, and statistical treatment so a reviewer who never ran the method can reproduce the conclusion. That audit trail is what converts HPLC from a technique into a pharmaceutical control strategy.
